Effects of Serine 129 Phosphorylation on α-Synuclein Aggregation, Membrane Association, and Internalization*

Received for publication, November 17, 2015, and in revised form, December 29, 2015 Published, JBC Papers in Press, December 30, 2015, DOI 10.1074/jbc.M115.705095

Filsy Samuel†‡, William P. Flavin§, Sobia Iqbal†, Consiglia Pacelli*, Sri Dusyantaan Sri Renganathan†, Louis-Eric Trudeau*, Edward M. Campbell§, Paul E. Fraser†‡‡, and Anurag Tandon†

From the †Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario M5T 2S8, Canada, the §Integrative Cell Biology Program, ‡Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois 60153, the **Departments of Pharmacology and Neurosciences, Central Nervous System Research Group (GRSNC), Faculty of Medicine, Université de Montréal, Québec H4T 1J4, Canada, and the Departments of Medical Biophysics and §§Medicine, University of Toronto, Toronto, Ontario M5T 2S8, Canada

Although trace levels of phosphorylated α-synuclein (α-syn) are detectable in normal brains, nearly all α-syn accumulated within Lewy bodies in Parkinson disease brains is phosphorylated on serine 129 (Ser-129). The role of the phosphoserine residue and its effects on α-syn structure, function, and intracellular accumulation are poorly understood. Here, co-expression of α-syn and polo-like kinase 2 (PLK2), a kinase that targets Ser-129, was used to generate phosphorylated α-syn for biophysical and biological characterization. Misfolding and fibril formation of phosphorylated α-syn isoforms were detected earlier, although the fibrils remained phosphatase- and protease-sensitive. Membrane binding of α-syn monomers was differentially affected by phosphorylation depending on the Parkinson disease-linked mutation. WT α-syn binding to presynaptic membranes was not affected by phosphorylation, whereas A30P α-syn binding was greatly increased, and A53T α-syn was slightly lower, implicating distal effects of the carboxyl-terminus and cytosolic α-syn. Endocytic vesicle-mediated internalization of pre-formed fibrils into non-neuronal cells and dopaminergic neurons matched the efficacy of unphosphorylated α-syn. Differential modifications and truncations that may affect both folding and intracellular neuronal transfer by limiting α-syn flexibility, modifying membrane association, complex formation, and degradation. Almost 90% of α-syn in Lewy bodies (LB) is phosphorylated on Ser-129 (Ser(P)-129), yet only 5% of α-syn in normal brains is similarly modified (10–12). Whether Ser(P)-129 α-syn affects aggregation, secretion, or uptake is equivocal, and subtle effects that are undetectable at low levels of expression in healthy tissue could be manifest cumulatively during disease progression as a result of pathological enrichment.

This study, we compared the biophysical and membrane/cellular interactions of recombinant nonphosphorylated and Ser(P)-129 α-syn to address whether phosphorylation affects its pathogenic characteristics. Differentially phosphorylated isoforms were generated by co-expressing wild-type (WT) and PD mutant (A30P and A53T) α-syn isoforms in Escherichia coli either without or with polo-like kinase 2 (PLK2), which uniquely phosphorylates Ser-129 on α-syn (13–16). Surprisingly, phosphorylation increased the self-assembly of the purified α-syn but had differential effects on membrane binding of monomeric α-syn and the internalization of aggregated α-syn isoforms. Although WT α-syn membrane binding was not sig-

*This work was supported in part by Canadian Institutes of Health Research Operating Grants MOP-84501 (to A. T.) and MOP-115056 (to P. E. F.). The authors declare that they have no conflicts of interest with the contents of this article.

†Supported in part by Edmond J. Safra Foundation fellowships.

‡These authors contributed equally to this work.

§Supported by the Illinois Chapter of the ARCS Foundation.

‡‡Supported by a fellowship from Parkinson Society of Canada.

¶Supported by the Krembil Foundation and Brain Canada.

**Supported by a Rapid Response Innovation Award from the Michael J. Fox Foundation.

††Supported by the Alzheimer Society of Ontario.

*To whom correspondence should be addressed: Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, 60 Leonard Ave., Toronto, Ontario M5T 2S8, Canada. Tel.: 416-507-6889; Fax: 416-603-6435; E-mail: a.tandon@utoronto.ca.

**The abbreviations used are: α-syn, α-synuclein; CIP, calf intestinal phosphatase; LB, Lewy bodies; PD, Parkinson disease; SN, substantia nigra; TH, tyrosine hydroxylase; VTA, ventral tegmental area.
nificantly affected, phosphorylation greatly enhanced that of A30P α-syn and reduced A53T α-syn binding. Moreover, despite the change in fibril formation, we observed that the relative effects of Ser(P)-129 on α-syn membrane binding were similar to its effects on α-syn internalization, suggesting that membrane binding is a rate-limiting step in α-syn internalization. However, endocytic vesicle rupture tended to be more pronounced with phosphorylated α-syn, even with α-syn isoforms with low levels of internalization, suggesting that even small amounts of α-syn loading per vesicle are sufficient for membrane permeabilization. These results are relevant to therapeutic strategies to reduce interneuronal α-syn transfer, and suggest that targeting α-syn binding to extracellular membranes may be a promising approach.

**Experimental Procedures**

**Preparation and Purification of α-Synuclein Fibrils**—Recombinant α-synuclein was expressed in *E. coli* with or without PLK2, purified as described previously (17), and stored in 20 mM Tris-Cl, pH 7.4. Fibril fractions were prepared by incubating purified proteins (1.5 mg/ml) at 37 °C and shaking at 200 rpm for ~7–10 days. Samples for electron microscopy (EM) and circular dichroism (CD) were prepared at every 3–4-day intervals. The extent of Ser-129 phosphorylation was assessed by Western blotting with an anti-Ser(P)-129 antibody (11A5 mouse monoclonal generously supplied by Elan Pharmaceuticals). Nonphosphorylated and phosphorylated α-syn were also analyzed by reverse phase HPLC (0.1% trifluoroacetic acid; 60% acetonitrile) using a C18 (Phenomenex) column (3-μm particle; 300-Å pore) with protein detection at 254 nm.

**Circular Dichroism Spectroscopy**—Far-UV CD spectra of purified fibrils in protein buffer were collected at room temperature using a Jasco-J175 spectrophotometer and 0.1-μm cuvette. Data were acquired at a step size of 0.2 nm with an averaging time of 3 s.

**Electron Microscopy and Image Processing**—Purified α-synuclein fibrils were adhered to glow-discharged, carbon-coated copper grids. Grids were stained, washed, and inspected as described previously (18).

**Digestion with Proteinase K (PK)**—An aliquot of 2 μg/ml proteinase K (Sigma) was added to 1.5 mg/ml purified α-synuclein fibrils. 15 μl of a fibril solution was taken out prior to the addition of PK, as a control for the untreated sample, and at different time points of treatment, an aliquot of 15 μl was taken for analysis. Each aliquot was quenched by the addition of SDS sample buffer and boiled for 10 min before being resolved on a 16% Tris-glycine SDS-PAGE for Western blotting.

**α-Syn Membrane Binding**—Synaptosomal membranes prepared from α-syn-deficient mice were incubated for 10 min at 37 °C with 1.5 mg/ml α-syn-deficient cytosol supplemented with 3 μg of recombinant non-phosphorylated or phosphorylated WT, A30P, or A53T α-syn as described (4). Membranes were then centrifuged at 24,000 × g for 10 min, washed twice with buffer to remove excess α-syn (25 mM HEPES, 125 mM KOAc, and 2.5 mM MgCl2), and resuspended in 1% SDS buffer for Western blotting. Bound HRP-conjugated anti-mouse or anti-rabbit IgG was revealed by chemiluminescence using ECL Plus (GE Healthcare) and quantified with a Li-Cor Odyssey Fc imager and Image Studio software (Li-Cor). All measurements were done in the linear range using standardized dilutions of mouse brain lysates or purified α-syn. Percentage of ratios of densitometric values for anti-syn immunoreactive bands of bound to total (bound and unbound) were calculated in each experiment (*n = 6*) and assessed using one-way analysis of variance and Tukey’s post hoc test.

**Cell Culture**—HeLa cells were maintained at 37 °C in Dulbecco’s modified Eagle’s medium (DMEM, Wisent) supplemented with 10% fetal bovine serum (Sigma). For staining and immunohistochemical studies, cells were seeded at a density of 15,000 cells/cm² on 12-mm glass coverslips.

Mesencephalic cultures were prepared according to a previously described protocol, with minor variations (19). Briefly, dissociated neurons micro-dissected from the substantia nigra (SNc) or ventral tegmental area (VTA) of P0–P2 C57BL6 mice were seeded on a monolayer of cortical astrocytes grown on collagen/poly-L-lysine-coated glass coverslips at a density of 100,000 cells/ml. Treatments with human α-syn fibrils, previously sonicated, were performed at 7 days *in vitro* for 24 h.

SH-SY5Y cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Hyclone) and 100 IU/ml penicillin, 100 μg/ml streptomycin, and 10 μg/ml ciprofloxacin. Cells were maintained in a 37 °C incubator with 5% CO2. SH-SY5Y/ChGal3 cells were made according to the protocol as described previously (20).

**Fibril Treatment**—α-syn fibrils (5 μg/ml) were sonicated for 30 s and added to the cell cultures. In some experiments, cultures were pre-treated with 80 μM dynasore for 30 min at 37 °C, which inhibits the endocytosis of clathrin-coated vesicles. Cells were subsequently co-incubated with 80 μM dynasore and/or 5 μg/ml fibrils for 20 min, after which the cultures were prepared for immunocytochemistry.

**Confocal Imaging**— Cultures were fixed for 30 min with 4% paraformaldehyde in PBS and permeabilized, and nonspecific binding sites were blocked. Cells were incubated overnight with a primary antibody solution containing 1% bovine serum albumin (BSA), 0.1% Triton X-100 in PBS, 5% goat serum, and 0.02% NaN3. HeLa cells were stained for 1 h with 100 nM actin phalloidin, 100 nM citochrome c, and 10 μg/ml ciprofloxacin. Cells were then stained for 30 min with 200 nM anti-syn and Alexa Fluor 488 secondary antibodies (Invitrogen). Primary antibodies used were rabbit tyrosine hydroxylase (TH) (Millipore, 1:2000) and α-syn (Invitrogen, 1:1000). After the final washes, coverslips with HeLa cells were placed on slides with mounting media (Vecasthield, Vector Laboratories) containing 4,6-diamidino-2-phenylindole (DAPI) to stain double-stranded DNA. Digital images (4–5 per condition in each experiment) were captured through ×40 objectives using a Leica 6000 microscope or LSM 750 confocal and Volocity image analysis system or Zen software.

For neuronal cultures, images were acquired using an Olympus Fluoview FV1000 confocal microscope (Olympus) using a ×60 oil-immersion objective. Ten TH-positive dopamine neurons were selected from each coverslip. All image quantification was performed using ImageJ (National Institutes of Health) software. Background correction was first applied at
Effects of α-Syn Phosphorylation

the same level for every image analyzed. TH images were then binarized, and the mask of these images was applied on the α-syn images. Only the α-syn signal co-localized with the TH signal was quantified. The total area of the α-syn signal was normalized on the total area of the TH signal. All quantification was blinded, and at least eight coverslips for each condition, from two different cultures, were used.

Vesicle Rupture Assays—All vesicle rupture assays with the purified recombinant α-syn were done in a blinded fashion. First, protein and solute concentrations, as well as total volume, were standardized across all four samples, according to previously published aggregation conditions (20). Specifically, 200 μl of purified α-syn (1 mg/ml) was prepared in a pH 7.4 buffer containing the following solute concentrations: 323.3 mM NaCl, 20 mM Tris-HCl, 9 mM Na2HPO4, 2.43 mM KCl, and 1.62 mM KH2PO4. Sample preparations were then incubated for 3 days at 37 °C under constant agitation, followed by storage at 4 °C. Aggregates were fluorescently labeled with DyLight 488 N-hydroxysuccinimide ester fluorophores (Thermo Scientific), according to the manufacturer’s protocol prior to use. Briefly, 100 μl of aggregated protein at 1 mg/ml was dialyzed into 0.1 M sodium phosphate buffer, pH 8.0, for 2 h using 10,000 molecular weight cutoff minidialysis units (Thermo Scientific). The protein solution was then transferred to the vial containing the dye and was labeled as per the supplier’s instructions for 30 min at room temperature. After incubation, the labeling reaction was quenched with 40 mM Tris (final concentration), and extensive dialysis was performed using 1,000 molecular weight cutoff dialysis units into a buffer containing 40 mM Tris and 150 mM NaCl for about 24 h to remove excess unlabeled dye.

SH-SY5Y mCherry-galectin 3 (chGal3) cells were allowed to adhere to fibronectin (Sigma)-treated glass coverslips and fixed with 3.7% formaldehyde (Polysciences) in 0.1 M PIPES buffer, pH 6.8, for 5 min. DAPI stain was then performed for 20 min in PBS. Coverslips were then mounted on glass slides and allowed to dry before image acquisition. Images were collected with a DeltaVision microscope (Applied Precision) equipped with a digital camera (CoolSNAP HQ; photometrics), using either a 1.4-numerical aperture × 100 objective lens or a 1.42-numerical aperture × 60 objective lens. Images were then deconvolved with SoftWoRx deconvolution software (Applied Precision). Tiff images and quantification data were collected from each image data file using Imaris software (Bitplane).

Deconvolved images were analyzed for puncta formation by use of the Surpass Mode of the Imaris software package (Bitplane). Specifically, a three-dimensional surface was created around chGal3+ puncta by designing an algorithm for each experiment that specifically detected punctate events that increased in intensity sufficiently above background fluorescence. This same algorithm was uniformly applied to each image in the data set, and the number of surfaces created by the algorithm was divided by the number of cells in the field to measure puncta per cell. Each experiment collected at least 20 images per treatment type.

Algorithm-detected values for number of chGal3+ puncta per cell were pooled across all experiments for statistical analysis. Values for mean number of chGal3+ puncta per cell induced by each α-syn treatment type from at least three independent experiments were compared with one another and to untreated cells by use of one-way analysis of variance and Tukey’s post hoc multiple comparison test. When a mean number of chGal3+ puncta per cell values from each experiment are normalized for Ser(P)-129 isoform to its non-Ser(P)-129 counterpart. HPLC elution of recombinant α-syn generated in the absence or presence of PLK2. C, Western blots probed with anti-Ser(P)-129 α-syn antibody (left blot) and total α-syn (right blot) showing dephosphorylation of A53T α-syn by CIP (alkaline phosphatase).

Results

Generation and Purification of Ser-129-phosphorylated α-syn—A, Western blot of phosphorylated α-syn and total α-syn purified from E. coli expressing WT, A30P, or A53T α-syn in the absence or presence of PLK2. Lower bands show a Coomassie stain of the purified protein. B, HPLC elution of recombinant α-syn generated in the absence or presence of PLK2. C, Western blots probed with anti-Ser(P)-129 α-syn antibody (left blot) and total α-syn (right blot) showing dephosphorylation of A53T α-syn by CIP (alkaline phosphatase).
phosphatase (CIP; alkaline phosphatase) removed the Ser(P)-
129 WT
A30P
A53T
FIGURE 2. Effects of Ser-129 phosphorylation on α-syn membrane bind-
ing. Synaptic membranes from α-syn-deficient mice were incubated with 1.5 mg/ml α-syn-deficient brain cytosol and 3 μg of recombinant human α-syn, either non-phosphorylated (−) or phosphorylated (p). The top panel shows representative Western blots of membrane-bound and unbound α-syn, and the lower panel shows α-syn binding as a percent of total α-syn (mean ± S.E., n = 6, *, p < 0.05).

do from the observation that the detergent-insoluble and aggre-
ging.

Results

Membrane Binding Properties of Monomeric Ser(P)-129 α-syn—We previously characterized the membrane binding of purified WT and PD-linked mutant α-syn to presynaptic mem-
branes isolated from α-syn-deficient mouse brain (4, 16). How-
ever, the impact of α-syn phosphorylation at its carboxyl-terminal domain, the primary pathological post-translational modifi-
cation, though distal to the amino-terminal membrane binding domain, is unknown. Therefore, we assessed normal and mutant α-syn membrane binding with or without Ser(P)-
129. Synaptosome membranes were incubated for 10 min at
37 °C with constant shaking, and aliquots were
periodically removed to assess circular dichroism (CD) spectra
and for analysis by electron microscopy (EM). As shown by the
CD spectra in Fig. 3A, the Ser-129-phosphorylated α-syn iso-
forms appeared to transition earlier from random coil to typical
β-sheet (minima at ~220 nm). In accord, all α-syn versions
bearing Ser(P)-129 were also prone to form longer and more
intricate fibril networks before their nonphosphorylated counter-
parts as shown by negative-stain electron micros-

Pathological α-syn fibrils isolated from PD or dementia with
Lewy bodies brains display pronounced resistance to protei-
nases (25–27). However, the fibrils generated from phos-
phorylated α-syn did not show enhanced tolerance to protease K
compared with nonphosphorylated forms (A30P is shown in
Fig. 3C). Although the majority of the α-syn fibrils were not
SDS-resistant and with similar mobility as monomeric α-syn, a
multiple high molecular weight α-syn species can be detected
after 10 days of incubation. More low mobility α-syn bands
were present in the phosphorylated α-syn lanes, but there was
no obvious difference in protease K sensitivity between the
phosphorylated nond phosphatase fibrils. Similarto monom-
eric Ser(P)-129 α-syn, these phosphorylated A30P fibrils
were also sensitive to dephosphorylation by CIP (Fig. 3D).

Cellular Uptake of Ser(P)-129 α-syn by Non-neuronal and
Neuronal Cells—To evaluate the effects of Ser-129 phosphory-
ation on α-syn cellular uptake, HeLa cells were exposed to
sonicated preformed α-syn fibrils for 20 min, and uptake was
evaluated by immunofluorescence. These non-neuronal cells
have a large cytoplasmic area that is more amenable to inter-
nalization analyses than neurons. In all experiments, antibodies
to α-syn labeled puncta of various sizes, suggestive of α-syn
accumulation either at the cell surface or following internaliza-
tion. These were compared with control experiments with
either no added extracellular aggregates or with preformed fibrils composed of islet amyloid polypeptide (Fig. 4). Neither of
these control conditions induced α-syn immunoreactivity, indi-
cating that α-syn labeling detected after the exposure to
extracellular preformed α-syn fibrils was indeed due to cell sur-
face binding and internalization of the exogenous α-syn. All
fibrillar α-syn isoforms showed some accumulation by HeLa
cells, although Ser-129 phosphorylation affected internaliza-
tion of WT and mutant α-syn differentially. As with the binding
to presynaptic membranes, internalization of WT and Ser(P)-
129 WT α-syn was not significantly different, but both PD
mutants were significantly affected by phosphorylation. Similar
to their respective membrane binding properties, Ser-129 phos-
phorylation increased A30P uptake but reduced that of A53T α-
syn.

To determine whether α-syn uptake is mediated by dynamin-
dependent endocytosis, we also performed experiments in the
presence of a dynamin inhibitor (28). Blockade of endocytosis
with dynasore eliminated the perinuclear α-syn immunoreac-
tivity such that the accumulated α-syn was predominantly dis-
tributed along the cell periphery in close apposition to the
plasma membrane (Fig. 4A). Moreover, quantification of the
immunofluorescence indicated that the net recovery of α-syn
within the HeLa cells was largely unaffected (Fig. 4B). This pat-
tern is consistent with the inhibition of endocytic retrieval and

Analysis of in Vitro Aggregation—A primary question arising
from the observation that the detergent-insoluble and aggre-
gated α-syn in LB is highly phosphorylated is whether the phos-
phorylation influences α-syn self-assembly. To address the role
of Ser(P)-129 in α-syn fibril formation, the three α-syn isoforms
and their phosphorylated versions were incubated in neutral
pH buffer at 37 °C with constant shaking, and aliquots were

Effects of α-Syn Phosphorylation
suggests that events preceding endocytosis, such as α-syn membrane binding and sequestration, remain intact and that its internalization is vesicle-dependent.

We evaluated the accumulation of exogenous α-syn fibrils by primary dopaminergic mouse neurons (19, 29), a cell population known to be particularly vulnerable in PD. Isolated neurons from either substantia nigra (SN) or VTA, grown on coverslips for 7 days on an astrocyte monolayer, were treated with α-syn fibrils and then examined for α-syn uptake by confocal imaging after identification of neurons with TH immunoreac-

FIGURE 3. Characterization of α-syn fibrils. Purified non-phosphorylated (WT, A30P, A53T) or phosphorylated (WT-p, A30P-p, A53T-p) α-syn were subjected to 200 rpm shaking at 37 °C. At the indicated times, aliquots of α-syn were assessed for protein secondary structure as determined by circular dichroism (A) and by negative stain transmission electron microscopy (B). Both parameters indicate that each phosphorylated α-syn isoform displayed accelerated β-sheet formation and a higher propensity to form fibrils as compared with its non-phosphorylated version. d, day. Exposure to proteinase K (C) or calf intestinal phosphatase (D) indicated that proteinase sensitivity was unchanged and that the α-syn fibril formation did not impede dephosphorylation, at least by 10 days of aging in vitro (A30P shown). Scale bars in B are 100 nm.
vatility. To assess uptake specifically into dopaminergic neurons, α-syn fluorescence that co-localized with tyrosine hydroxylase was quantified. After 24 h of exposure to sonicated pre-formed fibrils, punctate α-syn labeling could be detected in TH-positive neurons treated with either phosphorylated or non-phosphorylated α-syn (Fig. 5A). Quantification of the α-syn fluorescence relative to TH revealed a pattern similar to uptake in the non-neuronal cells (Fig. 5B). For the SN dopaminergic neurons, there was a significant increase in Ser(P)-129-induced uptake of WT and A30P α-syn and a minor trend to lower A53T α-syn that was not statistically significant. In contrast, the impact of phosphorylation on fibril uptake into VTA dopaminergic neurons was closer to the HeLa cells; WT α-syn was unaffected, whereas A30P uptake was increased, and A53T uptake was reduced.

**Effects of α-syn Fibrils on Vesicle Rupture**—Prion-like propagation of abnormal α-syn structure necessitates direct interaction between extracellular misfolded α-syn and normal intracellular α-syn in order for templating to occur. Thus, pathways that mediate α-syn intermixing of intra- and extracellular α-syn are of particular interest. To measure the ability of α-syn to access the cytoplasm of cells following endocytosis, we exploited the relocalization of galectin-3 that occurs following vesicle permeabilization. The loss of vesicle membrane integrity permits galectin-3 access to lumina that are bound by the carbohydrate recognition domain present in galectin-3, and therefore it has been utilized to monitor vesicle rupture induced by bacterial and viral pathogens during infection (30, 31). We have previously reported that α-syn aggregates induce galectin-3 relocalization to intracellular vesicles containing α-syn following endocytosis (20). We therefore used this assay to investigate the ability of endocytosed non-phosphorylated and phosphorylated α-syn to rupture vesicular membranes and to test the hypothesis that disease-associated familial missense mutations or post-translational modifications can differentially affect the potency of α-syn entry via this disruptive mechanism.

We treated SH-SY5Y neuroblastoma cells stably expressing mCherry-galectin-3 (chGal3) with DyLight 488-labeled WT, A30P, or A53T α-syn fibrils in either their non-phosphorylated or Ser-129-phosphorylated forms. Following a 24-h incubation in the cell culture medium, we assessed the formation of chGal3-positive puncta as a measurement of vesicle rupture induction. Each type of α-syn was able to induce galectin-3 relocalization to intracellular punctate structures when compared with the diffuse cytoplasmic localization in untreated cells (Fig. 6A), and the profound co-localization of α-syn and chGal3+ puncta implicates α-syn as the causative agent of membrane permeabilization. Moreover, consistent with α-syn’s ability to associate with vesicular membranes, DyLight488-labeled α-syn aggregates can frequently be seen adopting a curved or arc-shaped localization at the periphery of chGal3+-ruptured vesicles.

**FIGURE 4. Inhibition of dynamin-dependent endocytosis reduces α-syn internalization.** A, HeLa cells were incubated with 5 μg/ml of either naive untreated or islet amyloid polypeptide controls, non-phosphorylated (WT, A30P, A53T), or phosphorylated (WT-p, A30P-p, A53T-p) α-syn fibrils. The sonicated fibrils were added in the presence or absence of the dynamin inhibitor, dynasore (240 nM). Figures are overlays of actin (phalloidin, green), α-syn (red), and DAPI (nuclei, blue), with the middle z-stack chosen as illustration. B, quantification of α-syn intensity between conditions in the presence and absence of dynasore (mean ± S.E., n = 4 –15, * p < 0.05).
To quantify vesicle rupture in a semi-automated unbiased fashion and to compare the relative abilities of each α-syn species to cause this membrane permeabilization, we used algorithm-assisted identification of chGal3 puncta in untreated and treated cells. This algorithm reliably identified cytoplasmic chGal3 puncta, and notably all but one type of aggregated α-syn, A30P, was able to induce a significant increase in the mean number of chGal3 puncta per cell compared with untreated cells (Fig. 6B). Additionally, although Ser(P)-129 A30P was the only Ser(P)-129 α-syn treatment to induce a statistically significant increase in chGal3+ puncta per cell compared with its non-Ser(P)-129 counterpart, both Ser(P)-129 WT and Ser(P)-129 A53T showed trends above their non-phosphorylated counterparts, although not reaching statistical significance. Furthermore, when the mean number of chGal3+ puncta per cell values was normalized so that Ser(P)-129 isoforms were expressed as a fold change relative to their non-Ser(P)-129 counterparts within the same experiments, all Ser(P)-129 α-syn types show an ~50% increase in the mean number of chGal3+ puncta per cell relative to their non-Ser(P)-129 counterparts (Fig. 6C).

Again, although the only mutant that exhibited a statistically significant increase was Ser(P)-129 A30P, both Ser(P)-129 WT and Ser(P)-129 A53T showed trends that were not statistically significant. This suggests that Ser-129 phosphorylation may impact the potency of vesicle rupture following endocytosis, as exemplified by the A30P α-syn, which showed the greatest differential between its phosphorylated and non-phosphorylated forms in terms of membrane binding and internalization.

**Discussion**

α-Syn undergoes multiple post-translational modifications (phosphorylation, ubiquitination, sumoylation, acetylation, nitration, and truncation). Of these, however, Ser-129-targeted phosphorylation is preferentially and consistently up-regulated in PD and related synucleinopathies (10, 12, 32–36). More than 90% of α-syn is phosphorylated on Ser-129 in LB as compared with less than 5% in unaffected brains, suggesting that phosphorylation may influence its rate of aggregation and toxicity or its overall stability. However, the various studies that have examined the specific consequences of Ser-129 phosphorylation have failed to reach a consensus. In vitro biochemical phosphorylation assays have yielded inconsistent effects on α-syn aggregation, with studies showing both increased and decreased α-syn fibril formation (10, 37, 38). Similarly, modulation of Ser(P)-129 α-syn levels in cells by ectopic expression of various serine kinases known to phosphorylate α-syn have also been equivocal on the function of phosphorylation, suggesting promotion (10, 39–42) or either inhibition or no effect (37, 43–48) on inclusion formation. Finally, the use of α-syn S129A or S129D mutants to either prevent or mimic phosphorylation in various *in vivo* models has also yielded conflicting results. Co-expression of S129A α-syn in flies rescued the neuronal loss induced by WT α-syn expression, and correspondingly, S129D α-syn was associated with increased pathology (39, 44, 47, 49, 50). However, contrary relationships were observed in other models, including yeast, mammalian cells, *Caenorhabditis elegans*, and rodents (51–53), and no phenotype was detected in α-syn-deficient mice expressing either S129A or S129D transgenes (54). Not only has the function of Ser(P)-129 α-syn modification eluded explanation, but the stage at which this modi-
FEBRUARY 26, 2016 • VOLUME 291 • NUMBER 9

Effects of α-Syn Phosphorylation

FIGURE 6. Effects of Ser(P)-129 α-syn fibrils on vesicle rupture assay. A, exposure of SH-SY5Y cells, stably expressing chGal3, to non-phosphorylated (WT, A30P, A53T) or phosphorylated (WT-p, A30P-p, A53T-p) α-syn fibrils induced galectin-3 (red) and α-syn (green) puncta. Regions of interest (white square) in the left-most panels are shown at higher magnification in the right panels. White arrows show co-localized galectin-3 (red) and α-syn (green) puncta. Histograms show quantification of either chGal3+ puncta per cell (mean ± S.E., n = 3; *, p < 0.05 versus untreated; #, p < 0.05 versus non-phosphorylated α-syn) (B) or impact of phosphorylation on vesicle rupture normalized to the non-phosphorylated isoforms (mean ± S.E., n = 3; *, p < 0.05 versus non-phosphorylated α-syn) (C).

Effects of phosphorylation occurs is also unclear. There is some evidence that suggests that α-syn can also be phosphorylated post-fibrillation (14, 15, 45, 55), perhaps as an effort to clear aggregated α-syn (56), which is consistent with Ser(P)-129 α-syn accumulation during proteasome inhibition and elevated autophagy-mediated α-syn degradation with PLK2 overexpression (16, 57). Because of the overall lack of consensus across these many studies, further confounded by variations in the extent of α-syn phosphorylation and potential off-target effects of overexpressed kinases and α-syn mutants, we generated highly pure phosphorylated recombinant α-syn to examine its biophysical and biological properties. This was done to avoid partial phos-
Effects of α-Syn Phosphorylation

phorylation, noted by previous studies (55), which assessed mixtures of non-phosphorylated and phosphorylated α-syn.

Our co-expression of PLK2 and α-syn in E. coli provided consistent and ample yields of highly phosphorylated α-syn. We noted that each of the Ser-129 phosphorylated α-syn isoforms tended to lose random coil structure earlier, with a concomitant shift to β-sheet structure, in comparison with their non-phosphorylated counterparts. This structural change was also detected by EM as an earlier appearance of assembled fibrils by all three phosphorylated α-syn isoforms. Thus, in our hands, this pro-aggregation effect is similar to experiments with α-syn bearing carboxyl-terminal truncations (58–61). The phosphorylated fibrils remained sensitive to both phosphatase-mediated dephosphorylation and to proteinase K digestion. The latter properties suggest that the tertiary and quaternary structures of the assembled fibrils, although visible as long fibrils, were early stage fibrils and not compacted sufficiently to prevent enzymatic access. Also, given that the conversion from monomer to oligomer and fibril is continuous, all three forms are likely present in our preparations. Several lines of evidence suggest that α-syn fibrils undergo some form of aging during seeding, not only in in vitro self-assembly assays (62), but also in α-syn prion-like infection studies (63). Although the impact of phosphorylation on repeated seeding and propagation remains unclear, the recruitment of non-phosphorylated α-syn by the phosphoprotein is particularly relevant to the spread of phosphorylated α-syn from LB to proximal healthy neurons. Further study using the highly phosphorylated α-syn fibrils described here can help clarify the underlying mechanisms.

The involvement of post-translational modifications, particularly phosphorylation, on intercellular α-syn movement linking prion-like mechanisms to the initiation and propagation of α-syn pathology in PD is not understood. In this scheme, the internalization of extracellular misfolded α-syn can be considered a multistep pathway involving cell surface interaction, internalization, and access to intracellular compartments containing endogenous α-syn or turnover mediated by protein degradation machinery. Our previous report found only a small impact of α-syn phosphorylation on its intracellular partitioning between membrane and cytosolic fractions (16), although others have reported an increase in nuclear localization (53, 64, 65) or reduced lipid binding (10, 32, 66). In contrast, this study used purified Ser(P)-129 α-syn and enabled us to measure its membrane binding properties and internalization more directly. Unlike the increased propensity to aggregate, Ser-129 phosphorylation did not uniformly impact membrane binding of monomeric WT, A30P, and A53T α-syn with differential effects on the α-syn isoforms. Phosphorylation of WT α-syn had no effect on its membrane association, but it greatly enhanced A30P α-syn binding and tended to reduce that of A53T α-syn. Despite our lack of functional understanding of carboxyl-terminal modifications, these observations are consistent with evidence that long range carboxyl-terminal effects impact helix formation and binding efficiency of the amino-terminal amphipathic domain (67, 68). In addition, extracellular α-syn binding to biological membranes may also involve coordination with lipids and additional protein components in lipid raft domains via the carboxyl terminus (24, 69, 70). For example, there is evidence that the portion of the carboxyl-terminal domain containing the serine 129 residue of synaptic vesicle-bound α-syn can interact with synaptobrevin (6). Although no protein interactors for the extracellular α-syn carboxyl-terminal domain have been reported, recently heparan sulfate proteoglycans have suggested to act as receptors for α-syn internalization (71).

The effect of phosphorylation on internalization of preformed α-syn fibrils was assessed by immunofluorescence in both neuronal and non-neuronal cells, and it appeared to mirror the membrane binding properties of each α-syn isoform. In both HeLa cells and dopaminergic neurons, the Ser-129 phosphorylation had only a subtle impact on WT α-syn internalization, although the increase in SN neurons reached statistical significance. In contrast, phosphorylation had opposing effects on the α-syn PD mutants, substantially increasing A30P and reducing A53T α-syn accumulation. In the presence of the dynamin inhibitor dynasore, instead of the expected perinuclear accumulation, the α-syn immunoreactivity was excluded from the cell interior and retained at the periphery adjacent to the plasma membrane. Despite the qualitatively different intracellular localization, the overall signal for each α-syn isoform was not greatly reduced, indicating normal cell surface binding and sequestration, and consistent with a blockade of dynamin-dependent endocytosis (69, 72–74). Interestingly, the dynasore treatment accentuated the differential accumulation of the non-phosphorylated and phosphorylated WT α-syn, raising the possibility that the endocytosed α-syn may normally undergo trafficking to organelles with protein degradation machinery.

There is compelling evidence that extracellular misfolded higher order α-syn multimers can undergo uptake by nearby cells, and a prion-like mechanism has been proposed for the spread of misfolded α-syn by cell-to-cell transfer and self-perpetuating recruitment of normal α-syn molecules into aberrant conformations (75–80). The cellular mechanisms by which extracellular or luminal α-syn can encounter endogenous α-syn, which is predominantly cytosolic, are unclear, although one pathway that could mediate this encounter is via the rupture of endocytic vesicle membranes by internalized α-syn (20). Damage to transport vesicles could therefore permit misfolded luminal α-syn to gain access to the cytosolic compartment where it may have an opportunity to propagate β-sheet structure to endogenous normal α-syn. We therefore compared the relative abilities of WT, A30P, and A53T α-syn fibrils to induce vesicle rupture in both their Ser-129 phosphorylated and non-phosphorylated forms. As measured by relocation of mCherry-galectin-3, the effect of Ser-129 phosphorylation tended to increase vesicle rupture potency by about 50% for all α-syn types above non-phosphorylated counterparts, although this was statistically significant only for A30P α-syn. It should be noted that this assay measures vesicle permeability rather than α-syn loading, such that any vesicle membrane damage would yield an all or none result. Thus, the inability of the non-phosphorylated A30P α-syn to increase chGa3+ puncta above untreated controls may be governed by its poor association
with lipid membranes as compared with the other α-syn isoforms.

Overall, our results show that, despite consistent effects of Ser-129 phosphorylation on fibril formation of each of the three α-syn isoforms, there was considerable disparity with their membrane binding and internalization properties, as compared with vesicle rupture. From this, we propose that aggregation, per se, is likely not a sufficient determinant for the internalization of misfolded proteins, which is more strongly correlated with cell surface binding. This was most evident for the A30P α-syn, which showed a significant enhancement of membrane binding in its phosphorylated state relative to the other α-syn isoforms, and corresponded well with its internalization and vesicle rupture. Vesicle rupture by WT and A53T forms, however, did not show the same trends observed in membrane binding and internalization assay. In these cases, phosphorylation induced a slight increase in vesicle rupture that was not statistically significant. The simplest explanation for this discordance is that vesicle rupture is mediated by the oligomeric/fibrillar forms of α-syn, which were increased by phosphorylation in these studies. It is also tempting to speculate that these aggregation properties of phosphorylated α-syn may underlie the early onset PD caused by α-syn gene multiplication and the mutant forms. We suspect that the statistically significant increase in vesicle rupture observed by phosphorylated A30P, relative to its non-phosphorylated counterpart, is likely reflective of both Ser(P)-129 rescue of normally weak membrane binding/internalization in the non-Ser(P)-129 isoform as well as the increased potency of vesicle rupture that fibrillar species likely possess, although we cannot separate these properties using this assay. Current hypotheses of intercellular prion-like binding/internalization in the non-Ser(P)-129 isoform as well as the internalization of misfolded protein to the cell exterior, and this step may be relevant for therapeutic blockade.

Author Contributions—P. E. F. and A. T. coordinated the study, and A. T. wrote the original version of the paper. F. S., W. P. F., S. I., C. P., and S.-D. S.-R. acquired the data. E. M. C., L.-E. T., P. E. F., and A. T. made substantial contributions to the conception and design of the investigation as well as analysis and interpretation of the findings. All authors contributed to drafting the manuscript as well as revising it for clarity and intellectual contents. All authors also approved the final version of the manuscript.

Acknowledgments—We thank Vivian Ng, Kyung Han, and Ling Wu for technical support in the generation and characterization of phospho-α-syn: Tammy Langman for synaptosome isolations; and Marie-Josée Bourque for help in the preparation of primary mesencephalic cultures. We also thank John P. Anderson (Elan Pharmaceuticals) for the generous provision of monoclonal 11A5 antibody recognizing Ser(P)-129 α-syn.

References

1. Davidson, W. S., Jonas, A., Clayton, D. F., and George, J. M. (1998) Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443–9449
2. Perrin, R. J., Woods, W. S., Clayton, D. F., and George, J. M. (2000) Interaction of human α-synuclein and Parkinson disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem. 275, 34393–34398
3. Wislet-Gendebien, S., D’Souza, C., Kawarai, T., St George-Hyslop, P., Westaway, D., Fraser, P., and Tandon, A. (2006) Cytosolic proteins regulate α-synuclein dissociation from presynaptic membranes. J. Biol. Chem. 281, 32148–32155
4. Wislet-Gendebien, S., Visanji, N. P., Whitehead, S. N., Marsillo, D., Hou, W., Figyes, D., Fraser, P. E., Bennett, S. A., and Tandon, A. (2008) Differential regulation of wild-type and mutant α-synuclein binding to synaptic membranes by cytosolic factors. BMC Neurosci. 9, 92
5. Fortin, D. L., Nemani, V. M., Vogmaier, S. M., Anthony, M. D., Ryan, T. A., and Edwards, R. H. (2005) Neural activity controls the synaptic accumulation of α-synuclein. J. Neurosci. 25, 10913–10921
6. Burré, J., Sharma, M., Tsetsenis, T., Buchmann, V., Etherton, M. R., and Südhof, T. C. (2010) α-Synuclein promotes SNARE-complex assembly in vitro and in vivo. Science 329, 1663–1667
7. Chen, R. H., Wislet-Gendebien, S., Samuel, F., Visanji, N. P., Zhang, G., Marsillo, D., Langman, T., Fraser, P. E., and Tandon, A. (2013) α-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. J. Biol. Chem. 288, 7438–7449
8. Olano, C. W., and Brundin, P. (2013) Parkinson disease and α-synuclein: is Parkinson disease a prion-like disorder? Mov. Disord. 28, 31–40
9. Beyer, K., and Ariza, A. (2013) α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol. Neurobiol. 47, 509–524
10. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., and Iwatsubo, T. (2002) α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160–164
11. Hasegawa, M., Fujiwara, H., Nonaka, T., Wakabayashi, K., Takahashi, H., Lee, V. M., Trojanowski, J. Q., Mann, D., and Iwatsubo, T. (2002) Phosphorylation of α-synuclein is ubiquitinated in α-synucleinopathy lesions. J. Biol. Chem. 277, 49071–49076
12. Anderson, J. P., Walker, D. E., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., Diep, L., Keim, P. S., Shen, X., Chataway, T., Schlossmacher, M. G., et al. (2006) Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739–29752
13. Inglis, K. J., Chereau, D., Brigham, E. F., Chio, S. S., Schöbel, S., Frigon, N. L., Yu, M., Caccavello, R. J., Nelson, S., Motter, R., Wright, S., Chian, D., Santiago, P., Soriano, F., Ramos, C., et al. (2009) Polo-like kinase 2 (PLK2) phosphorylates α-synuclein at serine 129 in central nervous system. J. Biol. Chem. 284, 2598–2602
14. Mbefo, M. K., Paleologou, K. E., Boucharaba, A., Oueslati, A., Schell, H., Fournier, M., Olschewski, D., Yin, G., Zweckstetter, M., Masliah, E., Kahle, P. J., Hirling, H., and Laschue, H. A. (2010) Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem. 285, 2807–2822
15. Waxman, E. A., and Giasson, B. I. (2011) Characterization of kinases involved in the phosphorylation of aggregated α-synuclein. J. Neurosci. Res. 89, 231–247
16. Visanji, N. P., Wislet-Gendebien, S., Oschipok, L. W., Zhang, G., Aubert, I., Fraser, P. E., and Tandon, A. (2011) Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes. J. Biol. Chem. 286, 35863–35873
17. Jo, E., McLaurin, J., Yip, C. M., St George-Hyslop, P., and Fraser, P. E. (2000) α-Synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275, 34328–34334
18. Potter, K. J., Scrocchi, L. A., Warnock, G. L., Ao, Z., Younker, M. A., Rosenberg, L., Lipsett, M., Verchere, C. B., and Fraser, P. E. (2009) Amyloid inhibitors enhance survival of cultured human islets. Biochim. Biophys. Acta 1790, 566–574
19. Fasano, C., Thibault, D., and Trudel, L. E. (2008) Culture of postnatal mesencephalic dopamine neurons on an astrocyte monolayer. Curr. Protop. Neurosci. Chapter 3, Unit 3.21
20. Freeman, D., Cedilos, R., Choyke, S., Lukic, Z., McGuire, K., Marvin, S., Burrage, A. M., Sudholt, S., Rana, A., O’Connor, C., Wiethoff, C. M., and
Campbell, E. M. (2013) α-Synuclein induces lysosomal rupture and ca
thesin dependent reactive oxygen species following endocytosis. PLoS On
e 8, e62143

21. Jo, E., Fuller, N., Rand, R. P., St George-Hyslop, P., and Fraser, P. E. (2002) De
defective membrane interactions of familial Parkinson disease mutant A30P α-synuclein. J. Mol. Biol. 315, 799 – 807

22. Jensen, P. H., Nielsen, M. S., Lakes, R., Dotti, C. G., and Goedert, M. (1998) Bindi
ing of α-synuclein to brain vesicles is abolished by familial Parkinson disease mutation. J. Biol. Chem. 273, 26292–26294

23. Bussell, R. Jr., and Eliezer, D. (2004) Effects of Parkinson disease-linked mu
tations on the structure of lipid-associated α-synuclein. Biochemistry 43, 4810–4818

24. Kubo, S., Nami, V. M., Chalkley, R. J., Anthony, M. D., Hattori, N., Mizuno, Y., Edwards, R. H., and Fortin, D. L. (2005) A combinatorial code for the interaction of α-synuclein with membranes. J. Biol. Chem. 280, 31664–31672

25. Miehe, H., Mizusawa, H., Iwatsubo, T., and Hasegawa, M. (2002) Bio-
chemical characterization of the core structure of α-synuclein filaments. J. Biol. Chem. 277, 19213–19219

26. Neumann, M., Kahle, P. J., Giasson, B. I., Ozmen, L., Muller, V., Jacobsen, H., Spooren, J. (2008) Spatiotemporal dynamics of ad

27. Neumann, M., Kahle, P. J., Kretzschmar, H. A., Haass, C., and Kahle, P. J. (2004) Regional distribution of protein kinase K-resistant α-synuclein corre

28. Harper, C. B., Popoff, M. R., McCluskey, A., Robinson, P. J., and Meunier, F. A. (2013) Targeting membrane traf

29. Maier, O., Marvin, S. A., Wodrich, H., Campbell, E. M., and Wiethoff, A. (2013) Galectin-3, a marker for vacuole lysis by invasive pathogens. Cell. Microbio

30. Okochi, M., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Meijer, L., Kahle, P. J., and Haass, C. (2000) Constitutive phosphorylation of the Parkinson disease associated α-synuclein. J. Biol. Chem. 275, 390–397

31. Kahle, P. J., Neumann, M., Ozmen, L., Muller, V., Jacobsen, H., Spooren, W., Fuss, B., Mallon, B., Macklin, W. B., Fujihara, H., Hasegawa, M., Iwatsubo, T., Kretzschmar, H. A., and Haass, C. (2002) Hyperphosphorylation and insolubility of α-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 3, 583–588

32. Saito, Y., Kawashima, A., Ruberu, N. N., Fujihara, H., Koyama, S., Sawabe, M., Arai, T., Nagura, H., Yamanouchi, H., Hasegawa, M., Iwatsubo, T., and Murayama, S. (2003) Accumulation of phosphorylated α-synuclein in ag

33. Koyama, S., Walter, J., Koyama, A., Nakajo, S., Baba, M., Iwatsubo, T., Unser, M., and Aebischer, P. (2009) Phospho

34. Saito, Y., Kawashima, A., Ruberu, N. N., Fujiwara, H., Koyama, S., Sawabe, M., Arai, T., Nagura, H., Yamanouchi, H., Hasegawa, M., Iwatsubo, T., Kretzschmar, H. A., and Haass, C. (2002) Misfolded pro

35. Dorval, V., and Fraser, P. E. (2006) Small ubiquitin-like modifier (SUMO)

36. Neumann, M., Neumann, M., Derau, R., Waalkens, E., Taymans, J. M., Baek

37. Paleologou, K. E., Schmid, A. W., Rospigliosi, C. C., Kim, H. Y., Lomberto, G. R., Fedenburg, R. A., Lansbury, P. T., Jr., Fernandez, C. O., Eliezer, D., Zweckstetter, M., and Lashuel, H. A. (2008) Phosphorylation at Ser-129 but not the phosphonetics Ser-129/E inhibits the fibbulation of α-synuclein. J. Biol. Chem. 283, 16895–16905

38. Schreurs, S., Gerard, M., Derau, R., Waalkens, E., Taymans, J. M., Baek

39. Smith, W. W., Margolis, R. L., Li, X., Troncoso, J. C., Lee, M. K., Dawson, V. L., Dawson, T. M., Iwatsubo, T., and Ross, C. A. (2005) α-Synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 25, 5544–5552

40. Arakawa, S., Wada, M., Goto, S., Karube, H., Sakamoto, M., Ren, C. H., Koyama, S., Nagasawa, H., Kimura, H., Kawanami, T., Kurita, K., Tajima, K., Daimon, M., Baba, M., Kido, T., et al. (2006) The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson disease. J. Neurosci. 26, 9227–9238

41. Takahashi, M., Ko, L. W., Kulathingal, J., Jiang, P., Sevlever, D., and Yen, S. H. (2007) Oxidative stress-induced phosphorylation, degradation and aggregation of α-synuclein are linked to upregulated CK2 and cathepsin D. Eur J. Neurosci. 26, 863–874

42. Wu, B., Liu, Q., Duan, C., Li, Y., Yu, S., Chan, P., Ueda, K., and Yang, H. (2011) Phosphorylation of α-synuclein upregulates tyrosine hydroxylase activity in MN9D cells. Acta Histochem. 113, 32–35

43. Lee, G., Tanaka, M., Park, K., Lee, S. S., Kim, Y. M., Junn, E., Lee, S. H., and Mournadian, M. M. (2004) Casein kinase II-mediated phosphorylation regu

44. Fiske, M., Valtieri, S., Solvang, K., Zorniak, M., White, M., Herrera, S., Konnikova, A., Brezinsky, R., and Debburman, S. (2011) Contribution of alanine-76 and serine phosphorylation in α-synuclein membrane associ

45. Waxman, E. A., and Giasson, B. I. (2008) Specificity and regulation of casein kinase-mediated phosphorylation of α-synuclein. J. Neuropathol. Exp. Neurol. 67, 402–416

46. Chau, K. Y., Ching, H. L., Schapira, A. H., and Cooper, J. M. (2009) Relation

47. Kragh, C. L., Lund, L. B., Febraro, F., Hansen, H. D., Gai, W. P., El-Agnaf, O., Richter-Landsberg, C., and Jensen, P. H. (2009) α-Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodend
groglial cells. J. Biol. Chem. 284, 10211–10222

48. Kuwahara, T., Tonegawa, R., Ito, G., Mitani, S., and Iwatsubo, T. (2012) Phosphorylation of α-synuclein protein at Ser-129 reduces neuronal dysfunc
tion by lowering its membrane binding property in Caenorhabditis elegans. J. Biol. Chem. 287, 7098–7109

49. Azeredo da Silveira, S., Schneider, B. L., Cifuentes-Diaz, C., Sage, D., Abb

50. Gonçalves, S., and Outeiro, T. F. (2013) Assessing the subcellular dynam

51. Kuwahara, T., Tonegawa, R., Ito, G., Mitani, S., and Iwatsubo, T. (2012) Phosphorylation of α-synuclein protein at Ser-129 reduces neuronal dysfunc
tion by lowering its membrane binding property in Caenorhabditis elegans. J. Biol. Chem. 287, 7098–7109

52. Azeredo da Silveira, S., Schneider, B. L., Cifuentes-Diaz, C., Sage, D., Ab

53. Gonçalves, S., and Outeiro, T. F. (2013) Assessing the subcellular dynam

54. Escobar, V. D., Kuo, Y. M., Orrison, B. M., Giasson, B. I., and Nussbaum, R. L. (2014) Transgenic mice expressing Ser-129 phosphorylation muta
tions in α-synuclein. Neurosci. Lett. 563, 96–100

55. Paleologou, K. E., Oueslati, A., Shakhed, G., Rospigliosi, C. C., Kim, H. Y., Lomberto, G. R., Fernandez, C. O., Schmid, A., Chegini, F., Gai, W. P., Chiappe, D., Moniatte, M., Schneider, B. L., Aebischer, P., Eliezer, D., et al.
Effects of α-Syn Phosphorylation

(2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits α-synuclein oligomerization, and influences synuclein-membrane interac-
tions. *J. Neurosci.* **30**, 3184–3198

56. Tenreiro, S., Reimão-Pinto, M. M., Antas, P., Rino, J., Wawryczka, D., Macedo, D., Rosado-Ramos, R., Amen, T., Waiss, M., Magalhães, F., Gomes, A., Santos, C. N., Kaganovich, D., and Outeiro, T. F. (2014) Phos-
phorylation modulates clearance of α-synuclein inclusions in a yeast model of Parkinson disease. *Plos Genet.* **10**, e1004302

57. Oueslati, A., Schneider, B. L., Aebischer, P., and Lashuel, H. A. (2013) Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity *in vivo*. *Proc. Natl. Acad. Sci. U.S.A.* **110**, E3945–E3954

58. Crowther, R. A., Jakes, R., Spillantini, M. G., and Goedert, M. (1998) Syn-
thetic filaments assembled from C-terminally truncated α-synuclein. *FEBS Lett.* **436**, 309–312

59. Hoyer, W., Cherny, D., Subramaniam, V., and Jovin, T. M. (2004) Rapid self-assembly of α-synuclein observed by *in situ* atomic force microscopy. *J. Mol. Biol.* **340**, 127–139

60. Li, W., West, N., Colla, E., Pletnikova, O., Troncoso, J. C., Marsh, L., Dawson, T. M., Jakála, P., Hartmann, T., Price, D. L., and Lee, M. K. (2005) Aggregation promoting C-terminal truncation of α-synuclein is a normal cellular process and is enhanced by the familial Parkinson disease-linked mutations. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 2162–2167

61. Games, D., Valera, E., Spencer, B., Rockenstein, E., Mante, M., Adame, A., Patrick, C., Ubhi, K., Nuber, S., Sacayon, P., Zago, W., Seubert, P., Barbour, R., Schenk, D., and Masliah, E. (2014) Reducing C-terminal-truncated α-synuclein by immunotherapy attenuates neurodegeneration and prop-
agation in Parkinson disease-like models. *J. Neurosci.* **34**, 9441–9454

62. Guo, J. L., Covell, D. J., Daniels, J. P., Iba, M., Stieber, A., Zhang, B., Riddle, D. M., Kwong, L. K., Xu, Y., Trojanowski, J. Q., and Lee, V. M. (2013) Distinct α-synuclein strains differentially promote τ inclusions in neu-
rons. *Cell* **154**, 107–117

63. Watts, J. C., Giles, K., Oehler, A., Middleton, L., Dexter, D. T., Gentleman, S. M., DeArmond, S. J., and Prusiner, S. B. (2013) Transmission of multiple system atrophy prions to transgenic mice. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 19555–19560

64. Yamada, M., Iwatsubo, T., Mizuno, Y., and Mochizuki, H. (2004) Overexp-
ression of α-synuclein in rat substantia nigra results in loss of dopamin-
ergic neurons, phosphorylation of α-synuclein and activation of caspase-9: resemblance to pathogenic changes in Parkinson disease. *J. Neurochem.* **91**, 451–461

65. Wakamatsu, M., Ishii, A., Uki, Y., Sakagami, J., Iwata, S., Ono, M., Mat-
sumoto, K., Nakamura, A., Tada, N., Kobayashi, K., Iwatsubo, T., and Yoshimoto, M. (2007) Accumulation of phosphorylated α-synuclein in dopaminergic neurons of transgenic mice that express human α-syn-
uclein. *J. Neurosci. Res.** 85**, 1819–1825

66. Pronin, A. N., Morris, A. J., Surguchov, A., and Benovic, J. L. (2000) Syn-
ucleins are a novel class of substrates for G protein-coupled receptor kinases. *J. Biol. Chem.* **275**, 26515–26522

67. Dedmon, M. M., Lindorff-Larsen, K., Christodoulou, J., Vendruscolo, M., and Dobson, C. M. (2005) Mapping long-range interactions in α-syn-
uclein using spin-label NMR and ensemble molecular dynamics simula-
tions. *J. Am. Chem. Soc.* **127**, 476–477

68. Ullman, O., Fisher, C. K., and Stultz, C. M. (2011) Explaining the structural plasticity of α-synuclein. *J. Am. Chem. Soc.* **133**, 19536–19546

69. Park, J. Y., Kim, K. S., Lee, S. B., Ryu, J. S., Chung, K. C., Choo, Y. K., Jou, L., Kim, J., and Park, S. M. (2009) On the mechanism of internalization of α-synuclein into microglia: roles of ganglioside GM1 and lipid raft. *J. Neu-
rochem.* **110**, 400–411

70. Ronzitti, G., Guzzi, G., Emmanuele, M., Lee, D., Sotnikova, T. D., Mus, L. V., Soubrane, C. H., Dallas, M. L., Thalhammer, A., Cingolani, L. A., Mochida, S., Gainetdinov, R. R., Stephens, G. J., and Chiergatti, E. (2014) Exogenous α-synuclein decreases raft partitioning of Cav2.2 channels inducing dop-
amine release. *J. Neurosci.* **34**, 10603–10615

71. Holmes, B. B., DeVos, S. L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., Ouidja, M. O., Brodsky, F. M., Marasa, J., Bagchi, D. P., Koztbaizer, P. T., Miller, T. M., Papy-Garcia, C. D., and Diamond, M. I. (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteo-
pathic seeds. *Proc. Natl. Acad. Sci. U.S.A.* **110**, E3138–E3147

72. Konno, M., Hasegawa, T., Baba, T., Miura, E., Sugeno, N., Kikuchi, A., Fiesel, F. C., Sasaki, T., Aoki, M., Itaya, Y., and Takeda, A. (2012) Sup-
pression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopa-
thy. *Mol. Neurodegener.* **7**, 38

73. Reyes, J. F., Lonser, T. T., Lamberts, J. T., Devine, M. J., Kunath, T., and Brundin, P. (2015) A cell culture model for monitoring α-synuclein cell-
to-cell transfer. *Neurobiol. Dis.* **77**, 266–275

74. Reyes, J. F., Rey, N. L., Bousset, L., Melki, R., Brundin, P., and Angot, E. (2014) α-Synuclein transfers from neurons to oligodendrocytes. *Glia* **62**, 387–398

75. Luk, K. C., Song, C., O’Brien, P., Stieber, A., Branch, J. R., Branden, K. R., Trojanowski, J. Q., and Lee, V. M. (2009) Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 20051–20056

76. Nonaka, T., Watanabe, S. L., Iwatsubo, T., and Hasegawa, M. (2010) Seeded aggregation and toxicity of α-synuclein and τ cellular models of neurodegenerative diseases1. *J. Biol. Chem.* **285**, 34885–34898

77. Desplats, P., Lee, H. J., Bae, E. J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., and Lee, S. J. (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 13010–13015

78. Hansen, C., Angot, E., Bergström, A. L., Steiner, J. A., Pieri, L., Paul, G., Outeiro, T. F., Melki, R., Kallunki, P., Fog, K., Li, J. Y., and Brundin, P. (2011) α-Synuclein propagates from mouse brain to graft dopamine neurons and seeds aggregation in cultured human cells. *J. Clin. Invest.* **121**, 715–725

79. Volpicelli-Daley, L. A., Luk, K. C., Patel, T. P., Tanik, S. A., Riddle, D. M., Stieber, A., Meaney, D. F., Trojanowski, J. Q., and Lee, V. M. (2011) Exog-
enous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. *Neuron* **72**, 57–71

80. Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., and Lee, V. M. (2012) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science* **338**, 949–953